Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study

Diabetologia

Volumn 55, Issue 2, 2012, Pages 432-442

  Beysen, C ^a   Murphy, E J ^c   Deines, K ^a   Chan, M ^a   Tsang, E ^a   Glass, A ^a   Turner, S M ^a   Protasio, J ^a   Riiff, T ^a   Hellerstein, M K ^a,b,c  

^a KINEMED INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bile acid sequestrant; Bile acid synthesis; Cholesterol synthesis; De novo lipogenesis; Endogenous glucose production; GLP 1; Gluconeogenesis; Glycogenolysis; Stable isotopes; Type 2 diabetes

Indexed keywords

BILE ACID; CHOLESTEROL; COLESEVELAM; FIBROBLAST GROWTH FACTOR 19; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; BILE ACID SYNTHESIS; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KINESIOTHERAPY; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; KINETICS; LIPID METABOLISM; LIPOGENESIS; LIVER; MALE; MIDDLE AGED; PLACEBOS; POSTPRANDIAL PERIOD;

EID: 84856701167     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2382-3     Document Type: Article

References (49)

1. W Insull Jr 2006 Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review South Med J 99 257 273 16553100 10.1097/01.smj.0000208120.73327.db
2. T Onishi N Sano H Takikawa 2002 Effect of colestimide on absorption of unconjugated bile acids in the rat jejunum J Gastroenterol Hepatol 17 697 701 12100616 10.1046/j.1440-1746.2002.02765.x 1:CAS:528:DC%2BD38XntVKiu7g%3D (Pubitemid 34748162)
3. H Herrema M Meissner TH van Dijk, et al. 2010 Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice Hepatology 51 806 816 19998408 10.1002/hep.23408 1:CAS:528:DC%2BC3cXks1Sqsr4%3D
4. AB Goldfine 2008 Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway Curr Opin Cardiol 23 502 511 18670263 10.1097/HCO.0b013e32830c6c37
5. P Lefebvre B Cariou F Lien F Kuipers B Staels 2009 Role of bile acids and bile acid receptors in metabolic regulation Physiol Rev 89 147 191 19126757 10.1152/physrev.00010.2008 1:CAS:528:DC%2BD1MXit1Cqtro%3D
6. K Ma PK Saha L Chan DD Moore 2006 Farnesoid X receptor is essential for normal glucose homeostasis J Clin Invest 116 1102 1109 16557297 10.1172/JCI25604 1:CAS:528:DC%2BD28XjsVWnurk%3D
7. Y Zhang FY Lee G Barrera, et al. 2006 Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc Natl Acad Sci U S A 103 1006 1011 16410358 10.1073/pnas.0506982103 1:CAS:528: DC%2BD28XhsVKgtLY%3D (Pubitemid 43212212)
8. B Cariou K van Harmelen D Duran-Sandoval, et al. 2006 The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J Biol Chem 281 11039 11049 16446356 10.1074/jbc.M510258200 1:CAS:528: DC%2BD28XjsFWjs7w%3D (Pubitemid 43855527)
9. S Katsuma A Hirasawa G Tsujimoto 2005 Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1 Biochem Biophys Res Commun 329 386 390 15721318 10.1016/j.bbrc.2005.01.139 1:CAS:528:DC%2BD2MXhsFSisbo%3D (Pubitemid 40255465)
10. M Watanabe SM Houten C Mataki, et al. 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 439 484 489 16400329 10.1038/nature04330 1:CAS:528:DC%2BD28XntFWmuw%3D%3D (Pubitemid 43152840)
11. SL Schwartz YL Lai J Xu, et al. 2010 The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study Metab Syndr Relat Disord 8 179 188 20059361 10.1089/met.2009.0049 1:CAS:528:DC%2BC3cXktlyitLY%3D
12. G Brufau F Stellaard K Prado, et al. 2010 Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism Hepatology 52 1455 1464 20725912 10.1002/hep.23831 1:CAS:528:DC%2BC3cXhtlejsrnE
13. G Brufau MJ Bahr B Staels, et al. 2010 Plasma bile acids are not associated with energy metabolism in humans Nutr Metab 7 73 10.1186/1743-7075-7- 73
14. MK Hellerstein RA Neese A Letscher P Linfoot S Turner 1997 Hepatic glucose-6-phosphatase flux and glucose phosphorylation, cycling, irreversible disposal, and net balance in vivo in rats. Measurement using the secreted glucuronate technique Metabolism: Clinical and Experimental 46 1390 1398 10.1016/S0026-0495(97)90137-2 1:CAS:528:DyaK1cXktFGrsw%3D%3D (Pubitemid 28053202)
15. A Gastaldelli A Casolaro M Pettiti, et al. 2007 Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes Clin Pharmacol Ther 81 205 212 17259945 10.1038/sj.clpt.6100034 1:CAS:528: DC%2BD2sXisFyrtLc%3D (Pubitemid 46174817)
16. C Beysen EJ Murphy T McLaughlin, et al. 2007 Whole-body glycolysis measured by the deuterated-glucose disposal test correlates highly with insulin resistance in vivo Diabetes Care 30 1143 1149 17259480 10.2337/dc06-1809 1:CAS:528:DC%2BD2sXmtFKnurc%3D (Pubitemid 46684639)
17. TH Van Dijk TS Boer R Havinga F Stellaard F Kuipers DJ Reijngoud 2003 Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots Anal Biochem 322 1 13 14705774 10.1016/j.ab.2003.07.008 (Pubitemid 37188550)
18. C Beysen EJ Murphy H Nagaraja, et al. 2008 A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes J Lipid Res 49 2657 2663 18641372 10.1194/jlr.M800165-JLR200 1:CAS:528: DC%2BD1cXhsVCjsL%2FI
19. MK Hellerstein M Christiansen S Kaempfer, et al. 1991 Measurement of de novo hepatic lipogenesis in humans using stable isotopes J Clin Invest 87 1841 1852 2022750 10.1172/JCI115206 1:CAS:528:DyaK3MXktVCltb0%3D
20. PH Bisschop RH Bandsma F Stellaard, et al. 2004 Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans Am J Clin Nutr 79 570 576 15051599 1:CAS:528: DC%2BD2cXivFykt7s%3D (Pubitemid 41103899)
21. RH Bandsma F Stellaard RJ Vonk, et al. 1998 Contribution of newly synthesized cholesterol to rat plasma and bile determined by mass isotopomer distribution analysis: bile-salt flux promotes secretion of newly synthesized cholesterol into bile Biochem J 329 699 703 9445401 1:CAS:528:DyaK1cXht1arsLs%3D (Pubitemid 28055196)
22. RA Neese JM Schwarz D Faix, et al. 1995 Gluconeogenesis and intrahepatic triose phosphate flux in response to fasting or substrate loads. Application of the mass isotopomer distribution analysis technique with testing of assumptions and potential problems J Biol Chem 270 14452 14466 7782307 10.1074/jbc.270.24. 14452 1:CAS:528:DyaK2MXmsVSit7w%3D
23. MP Christiansen PA Linfoot RA Neese MK Hellerstein 2000 Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes Diabetes 49 1691 1699 11016453 10.2337/diabetes.49.10.1691 1:CAS:528:DC%2BD3cXntVyhtrY%3D
24. JC Levy DR Matthews MP Hermans 1998 Correct homeostasis model assessment (HOMA) evaluation uses the computer program Diabetes Care 21 2191 2192 9839117 10.2337/diacare.21.12.2191 1:STN:280:DyaK1M%2Fls1CqtA%3D%3D (Pubitemid 28549174)
25. R Steele C Bjerknes I Rathgeb N Altszuler 1968 Glucose uptake and production during the oral glucose tolerance test Diabetes 17 415 421 4875169 1:CAS:528:DyaF1cXksFSnt7Y%3D
26. RA Neese D Faix C Kletke, et al. 1993 Measurement of endogenous synthesis of plasma cholesterol in rats and humans using MIDA Am J Physiol 264 E136 E147 8430782 1:CAS:528:DyaK3sXhvVOhu7Y%3D
27. MK Hellerstein RA Neese 1999 Mass isotopomer distribution analysis at eight years: theoretical, analytic, and experimental considerations Am J Physiol 276 E1146 E1170 10362629 1:CAS:528:DyaK1MXktlSqtbY%3D
28. VA Fonseca J Rosenstock AC Wang KE Truitt MR Jones 2008 Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy Diabetes Care 31 1479 1484 18458145 10.2337/dc08-0283 1:CAS:528:DC%2BD1cXhtVWlur3E
29. RB Goldberg VA Fonseca KE Truitt MR Jones 2008 Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy Arch Intern Med 168 1531 1540 18663165 10.1001/archinte.168.14.1531 1:CAS:528:DC%2BD1cXpvFKjsLc%3D
30. FJ Zieve MF Kalin SL Schwartz MR Jones WL Bailey 2007 Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes Clin Ther 29 74 83 17379048 10.1016/j.clinthera.2007.01.003 1:CAS:528:DC%2BD2sXjsVOnsrg%3D (Pubitemid 46414026)
31. B Ahren H Larsson JJ Holst 1997 Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 82 473 478 9024239 10.1210/jc.82.2.473 1:CAS:528:DyaK2sXhtVaqs7c%3D (Pubitemid 27068614)
32. M Zander S Madsbad JL Madsen JJ Holst 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study Lancet 359 824 830 11897280 10.1016/S0140-6736(02)07952-7 1:CAS:528:DC%2BD38XhvVWhtrk%3D (Pubitemid 34233752)
33. T Vilsboll T Krarup S Madsbad JJ Holst 2003 Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects Regul Pept 114 115 121 12832099 10.1016/S0167-0115(03)00111-3 1:CAS:528:DC%2BD3sXkvVCltLw%3D (Pubitemid 36773875)
34. L Chen J McNulty D Anderson, et al. 2010 Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats J Pharmacol Exp Ther 334 164 170 20413600 10.1124/jpet.110.166892 1:CAS:528:DC%2BC3cXos1KltL0%3D
35. M Kogire G Gomez T Uchida J Ishizuka GH Greeley Jr JC Thompson 1992 Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats Pancreas 7 15 20 1557341 10.1097/00006676-199201000-00003 1:STN:280:DyaK383ht1ynsQ%3D%3D
36. Q Shang M Saumoy JJ Holst G Salen G Xu 2010 Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1 Am J Physiol Gastrointest Liver Physiol 298 G419 G424 20044510 10.1152/ajpgi.00362.2009 1:CAS:528:DC%2BC3cXjsFGgt7g%3D
37. T Suzuki K Oba Y Igari, et al. 2007 Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia J Nippon Med Sch 74 338 343 10.1272/jnms.74.338 1:CAS:528:DC%2BD2sXht1KgtL3J (Pubitemid 47523077)
38. MK Hellerstein DJ Greenblatt HN Munro 1986 Glycoconjugates as noninvasive probes of intrahepatic metabolism: pathways of glucose entry into compartmentalized hepatic UDP-glucose pools during glycogen accumulation Proc Natl Acad Sci U S A 83 7044 7048 3462741 10.1073/pnas.83.18.7044 1:CAS:528:DyaL28Xls12mt7g%3D (Pubitemid 16002366)
39. J Katz JD McGarry 1984 The glucose paradox. Is glucose a substrate for liver metabolism? J Clin Invest 74 1901 1909 6392338 10.1172/JCI111610 1:CAS:528:DyaL2MXlvFOhsQ%3D%3D (Pubitemid 15197330)
40. KB Degn CB Juhl J Sturis, et al. 2004 One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes Diabetes 53 1187 1194 15111485 10.2337/diabetes.53.5.1187 1:CAS:528:DC%2BD2cXjslKiurc%3D (Pubitemid 38569002)
41. DS Edgerton KM Johnson DW Neal, et al. 2009 Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog Diabetes 58 243 249 18840785 10.2337/db08-0515 1:CAS:528:DC%2BD1MXptVCntw%3D%3D
42. RL Prigeon S Quddusi B Paty DA D'Alessio 2003 Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab 285 E701 E707 12773303 1:CAS:528: DC%2BD3sXosV2rur0%3D
43. K Yamagata H Daitoku Y Shimamoto, et al. 2004 Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1 J Biol Chem 279 23158 23165 15047713 10.1074/jbc.M314322200 1:CAS:528:DC%2BD2cXkt1GisLo%3D (Pubitemid 38685621)
44. TH Van Dijk A Grefhorst MH Oosterveer, et al. 2009 An increased flux through the glucose 6-phosphate pool in enterocytes delays glucose absorption in Fxr-/- mice J Biol Chem 284 10315 10323 19204003 10.1074/jbc.M807317200
45. RS Hundal M Krssak S Dufour, et al. 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes Diabetes 49 2063 2069 11118008 10.2337/diabetes.49.12.2063 1:CAS:528:DC%2BD3cXos1ejs7o%3D
46. K Einarsson S Ericsson S Ewerth, et al. 1991 Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism Eur J Clin Pharmacol 40 Suppl 1 S53 S58 2044645
47. K Einarsson K Hellstrom M Kallner 1974 The effect of cholestyramine on the elimination of cholesterol as bile acids in patients with hyperlipoproteinaemia type II and IV Eur J Clin Invest 4 405 410 4442440 1:CAS:528:DyaE2MXptlaqtg%3D%3D
48. T Lundasen C Galman B Angelin M Rudling 2006 Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man J Intern Med 260 530 536 17116003 10.1111/j.1365-2796.2006.01731.x 1:STN:280:DC%2BD28not1enug%3D%3D (Pubitemid 44772372)
49. S Bhatnagar HA Damron FB Hillgartner 2009 Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis J Biol Chem 284 10023 10033 19233843 10.1074/jbc.M808818200 1:CAS:528:DC%2BD1MXjvFKlu7k%3D